Caraco and Sun to merge

INICIO/Noticias Farmacéuticas | Posted 01/04/2011 post-comment0 Post your comment

Caraco Pharmaceutical Laboratories announced on 22 February 2011 that it had entered into a merger agreement with generics manufacturer Sun Pharmaceutical Industries and its wholly-owned subsidiary Sun Pharma Global.

picture27

US-based Caraco develops markets and distributes generic pharmaceuticals to the USA’s largest wholesalers, distributors, drugstore chains and managed care providers.

India’s Sun Pharma and Sun Global collectively own 75.8% of Caraco common stock.

The merger agreement provides that all shareholders of Caraco other than Sun Pharma and Sun Global will receive a cash payment of US$5.25 per share upon the closing of the transaction, rather than the US$4.75 initially proposed by Sun in December 2010.

The news comes despite Caraco being warned by the FDA back in September 2010 for violating manufacturing practices at its Cranbury facility in New Jersey, causing the FDA to withhold approval of pending new drug applications.

Related article

More drug recalls due to poor manufacturing

Source: Caraco

comment icon Comments (0)
Post your comment
Related content
El recorrido del biológico de continuación Pectuna (pertuzumab) en Irán
Cancer Cell V13I20
INICIO/Noticias Farmacéuticas Posted 29/02/2024
Fiocruz y Pfizer firman un acuerdo para el genérico de Xeljanz
Remicade V13F28
INICIO/Noticias Farmacéuticas Posted 30/01/2024
Genfar: La nueva marca de genéricos de Eurofarma en América Latina
10 AA008993
INICIO/Noticias Farmacéuticas Posted 12/12/2023
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010